NTP Announces New Board Members & Executive Chairman to Spearhead Further Company Development and Internationalization

NTP Nano Tech Projects S.r.l. (hereinafter referred as NTP) an emerging leader in the field of unprecedented optical detection for digital health applications today announced the appointment of several new Board members, including a new Executive Chairman, to spearhead and further drive recent launch of NTP´s first products in the field of digital pathology and digital hematology, as well as development of its unique molecular diagnostics platform.

Dr. Michael Lutz has been appointed as NTP´s new Executive Chairman. Dr. Lutz is a seasoned international life sciences executive with a significant wealth of entrepreneurial and start-up experience from the diagnostic and biotechnology industries. Most recently, Michael served as CEO at HepaRegeniX, a clinical stage biotech company in the field of advanced liver diseases. Before that, he was CEO of several Life Sciences companies which he successfully established or built-up to a successful exit. Michael holds a Ph. D in bioorganic chemistry from the ETH Zurich (Switzerland) and currently also serves on the Board of several other life sciences companies in Germany, the UK and Denmark.

Laura Ferro will join NTP´s Board in her capacity as experienced manager and entrepreneur in the Italian healthcare sector with strong academic background both in medical science and in business (MBA at Bocconi University, Milan). In November 2022 Laura was named among the 50 most powerful women in Italy by Fortune Italy, following the successful trade sale of her Nasdaq-listed family company Gentium to Jazz Pharmaceuticals in 2014 for 1bn USD and her successful new ventures. Laura is currently serving as Chairman of Bio4Dreams and Kither Biotech and acts as Investment Advisor in Claris Ventures.

The last new Board member is Stephen Allen. Stephen has enjoyed a 30-year career building a wide range of Life Science product and service companies. Before his current role as CBO and Board member at Depixus, he was most recently CEO of DNAe, the pioneers of semiconductor-based DNA sequencing. Prior to this, Stephen has held leadership positions at PerkinElmer, Mettler-Toledo and LGC Forensics. In the past, he was also a Board member and consultant at the Next Generation Sequencing pioneer Solexa where he helped to scale the company to product launch and trade sale to Illumina.

These new additions will join the NTP´s current Board members Dr. Adolfo Carloni, Rino Malaponti, Massimo Galavotti and Gianluca Maroncelli.

Commenting on the new Board members, NTP´s CEO Massimo Galavotti said: “We are thrilled to welcome such a high caliber team of seasoned biotech executives joining NTP as new Board members at such critical time where we have built and launched superior digital health platforms in the areas of pathology and hematology and are completing development of our Molecular Diagnostics appliance, featuring unparalleled virus and nanoparticles sized pathogens detection capabilities. At the same time, we would like to thank Gianluca Maroncelli for successfully and passionately acting as NTP´s Chairman of the Board since the Company’s inception and we look forward to his continued contributions both as Board member and COO of NTP”.